Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
DIMETANE-TEN is an injectable first-generation antihistamine containing brompheniramine maleate, approved in 1958 for allergic conditions and pruritic disorders. It works by competitively blocking H1 histamine receptors to provide rapid symptomatic relief. The injectable route enables faster onset compared to oral formulations in acute allergic reactions.
This legacy injectable antihistamine faces declining clinical adoption and revenue pressure; commercial teams are likely focused on retention and cost optimization rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study Evaluating Brompheniramine Maleate Liquid in Children and Adolescents
No active job postings are linked to DIMETANE-TEN, reflecting its legacy status and minimal commercial expansion. Roles supporting this product would focus on defending market share and managing the transition to generics rather than launching or growing a franchise.
Worked on DIMETANE-TEN at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.